Related Experiment Video
Updated: Apr 20, 2026
05:50
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
Published on: September 26, 2025
2.1K
Racing to define pharmaceutical R&D external innovation models.
Liangsu Wang1, Andrew Plump2, Michael Ringel3
1Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Drug Discovery Today
|December 3, 2014
Summary
Pharmaceutical companies are adopting external innovation strategies like academic collaboration and biotech partnerships to boost research and development (R&D) productivity and create novel therapies.
Area of Science:
- Pharmaceutical industry
- Biotechnology
- Drug discovery and development
Background:
- Declining research and development (R&D) productivity poses a significant challenge for the pharmaceutical sector.
- Increasing customer expectations necessitate the development of innovative and transformative therapies beyond incremental improvements.
- The need to reduce R&D costs drives the exploration of new innovation models.
Purpose of the Study:
- To review and compare various external innovation strategies employed by pharmaceutical companies.
- To identify current trends in pharmaceutical external innovation.
- To discuss factors influencing these innovation models and propose success metrics.
Main Methods:
- Literature review of pharmaceutical industry innovation strategies.
- Comparative analysis of different external innovation models (e.g., precompetitive collaboration, biotech partnerships, licensing, acquisitions).
- Identification of key trends and influencing factors in external innovation.
Main Results:
- Pharmaceutical companies are increasingly leveraging external sources for innovation to overcome R&D challenges.
- Key strategies include collaborations with academia, nurturing biotech start-ups, and strategic licensing and acquisitions.
- Emerging trends indicate a shift towards more proactive and diverse external innovation approaches.
Conclusions:
- External innovation is crucial for pharmaceutical companies to enhance R&D productivity and deliver transformative medicines.
- A combination of strategic partnerships and acquisitions is vital for a robust innovation pipeline.
- Developing leading indicators for success in external innovation models is essential for future strategy refinement.
More Related Videos
Related Concept Videos
01:29Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
142
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
142
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
514
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
514
01:27Pharmacodynamic Models: Overview
134
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
134
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
88
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
88
01:26Drug Discovery: Overview
13.6K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.6K
01:20Pharmacokinetic Models: Overview
2.8K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.8K